We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 12, 2021

Clinical Efficacy and Molecular Response Correlates of Adavosertib Combined With Cisplatin in mTNBC

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined With Cisplatin in Patients With Metastatic Triple-Negative Breast Cancer (mTNBC)
Clin. Cancer Res 2020 Dec 23;[EPub Ahead of Print], TE Keenan, T Li, T Vallius, JL Guerriero, N Tayob, BS Kochupurakkal, J Davis, RG Pastorello, RK Tahara, L Anderson, J Conway, MX He, E Shannon, R Godin, PK Sorger, AD D'Andrea, B Overmoyer, EP Winer, EA Mittendorf, EM Van Allen, GI Shapiro, SM Tolaney

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading